SEC Form 8-K Summary
Registrant: Tivic Health Systems, Inc. (NASDAQ: TIVC). The request metadata identifies Valion Bio, Inc., but the filing names Tivic Health Systems, Inc. as the registrant.
Reporting date: November 25, 2022; filed December 1, 2022. The filing reports a material agreement and related Regulation FD disclosure, not a periodic financial statement.
Business Context and Material Agreement
On November 25, 2022, Tivic entered into a Fulfillment Services Agreement with ALOM Technologies Corporation, effective November 28, 2022. ALOM will provide non-exclusive assembly, procurement, storage, returns, and fulfillment services for the Company’s U.S. end customers and retailers.
- Services will be performed under purchase orders issued by Tivic.
- Fees are based on fixed hourly rates and fixed unit pricing, subject to specified exceptions.
- Beginning April 1, 2023, Tivic will be subject to minimum periodic purchase requirements.
- The initial term is three years, followed by automatic annual renewals unless terminated.
- Termination is permitted for uncured breach, specified payment defaults, or convenience with 60 days’ written notice.
Certain agreement provisions were redacted under Regulation S-K Item 601(b)(10).
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, balance-sheet, or other periodic financial metrics. It also does not quantify the fees, minimum purchase commitments, or expected financial impact of the agreement.
Changes, Outlook, and Risks
The agreement changes Tivic’s U.S. fulfillment and supply-chain arrangements by engaging ALOM for assembly, procurement, storage, returns, and delivery support. Management’s press release regarding the agreement was furnished as Exhibit 99.1, but the filing text does not provide specific operating or financial guidance.
- Minimum purchase requirements beginning April 1, 2023 could create fixed or otherwise unavoidable costs if demand is lower than expected.
- Dependence on a third-party fulfillment provider may expose Tivic to execution, inventory, procurement, service-quality, and delivery risks.
- The agreement’s financial terms are not fully disclosed, and redacted provisions may contain additional material obligations.
- The filing includes customary forward-looking statement risks; actual results may differ materially because of known and unknown uncertainties.
Important Facts for Investors to Verify
- Review Exhibit 10.1 for the complete agreement, including redacted provisions, pricing exceptions, minimum purchase requirements, and termination terms.
- Assess the cash and earnings impact of ALOM’s fees and the minimum purchase obligations beginning April 1, 2023.
- Confirm whether subsequent filings disclose changes to the agreement, termination, fulfillment performance, or related commitments.
- Review Exhibit 99.1 and subsequent periodic reports for management’s expectations regarding customer demand, inventory, and operating results.
- Verify the correct registrant, as the supplied metadata references Valion Bio, Inc. while the filing identifies Tivic Health Systems, Inc.